Boston, MA-based healthcare venture capital firm Third Rock Ventures, LLC, has added Michael W. Bonney as a partner.
Mr. Bonney, who most recently served as chief executive officer of Cubist Pharmaceuticals Inc. (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until December 2014, brings to Third Rock extensive operational, commercial, and senior management expertise in the biopharmaceutical industry.
His prior experience includes leadership positions in biotechnology and pharmaceutical companies such as Biogen and Zeneca Pharmaceuticals (now AstraZeneca).
He also holds several board positions in leading biotechnology companies, including Alnylam Pharmaceuticals, Celgene Corporation, and in Whitehead Institute for Biomedical Research.
Launched in 2007 and led by Mark Levin, Kevin Starr, Robert Tepper, M.D., Alexis Borisy, Neil Exter, Kevin Gillis, Mark A. Goldsmith, M.D., Ph.D., Craig Muir, Cary Pfeffer, M.D., Third Rock Ventures is a healthcare venture capital firm that focuses on disruptive areas of science and medicine to discover, launch and build companies based on smart ideas meeting at the intersection of science, strategy, business and medicine providing more opportunities to impact the lives of patients.
The firm has $1.3 billion under management, approx. 35 companies in portfolio which target over 45 diseases.